Reports and Findings
Research
Efficacy, Immunogenicity, and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C. difficile InfectionJennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@telethonkids.org.au Clinical Research Manager Head, Vaccine Trials Group Jennifer completed her Diploma of Nursing in 1986 at
Research
Duration of Pertussis Immunity in Adults: A Study of Health Care WorkersJennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@telethonkids.org.au Clinical Research Manager Head, Vaccine Trials Group Jennifer completed her Diploma of Nursing in 1986 at
Research
AusVaxSafetyChristopher Peter Peter Tom Blyth Jacoby Richmond Snelling MBBS (Hons) DCH FRACP FRCPA PhD BA (Hons) MSc MBBS MRCP(UK) FRACP BMBS DTMH GDipClinEpid PhD FRACP Centre Head, Wesfarmers Centre of Vaccines and Infectious Diseases; Co-Head, Infectious
Research
A study to determine the safety and immunogenicity of 10-valent and 13-valent pneumococcal conjugate vaccines in Papua New Guinean childrenDeborah Peter Peter Lehmann Jacoby Richmond AO, MBBS, MSc BA (Hons) MSc MBBS MRCP(UK) FRACP Honorary Emeritus Fellow Biostatistician Head, Vaccine Trials Group Peter.Jacoby@telethonkids.org.au Honorary Emeritus Fellow Biostatistician Head, Vaccine
Research
A Phase II Randomized, Controlled, Observer-Blinded Study, Conducted to Describe the Immunogenicity, Safety, and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine When Administered to Healthy ToddlersJennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@telethonkids.org.au Clinical Research Manager Head, Vaccine Trials Group Jennifer completed her Diploma of Nursing in 1986 at
Research
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY)Jennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@telethonkids.org.au Clinical Research Manager Head, Vaccine Trials Group Jennifer completed her Diploma of Nursing in 1986 at
Research
The Long-term Impact of Serogroup B Invasive Meningococcal Disease (IMD) in Australian Adolescents and Young Adults: AMEND studyChristopher Peter Blyth Richmond MBBS (Hons) DCH FRACP FRCPA PhD MBBS MRCP(UK) FRACP Centre Head, Wesfarmers Centre of Vaccines and Infectious Diseases; Co-Head, Infectious Diseases Epidemiology, Wesfarmers Centre of Vaccines and Infectious Diseases
Research
Protective Vaccine Responses in Infants after Maternal Pertussis Vaccination (PRIME) StudyChristopher Jennifer Peter Blyth Kent Richmond MBBS (Hons) DCH FRACP FRCPA PhD RN MBBS MRCP(UK) FRACP Centre Head, Wesfarmers Centre of Vaccines and Infectious Diseases; Co-Head, Infectious Diseases Epidemiology, Wesfarmers Centre of Vaccines and
Research
Pertaprime: An investigator-driven phase II-III randomised, observer-blind, controlled trial to demonstrate non-inferior immunogenicity of Pertagen® in comparison to Boostrix® in healthy young Australian adults aged 18-25 yearsJennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@telethonkids.org.au Clinical Research Manager Head, Vaccine Trials Group Jennifer completed her Diploma of Nursing in 1986 at
Research
BCG vaccination to Reduce the impact of COVID-19 in Australian healthcare workers following Coronavirus Exposure (BRACE) TrialJennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@telethonkids.org.au Clinical Research Manager Head, Vaccine Trials Group Jennifer completed her Diploma of Nursing in 1986 at